X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used to fund the clinical advancement of company lead product BETR-001 (2-Bromo-Lysergic Acid Diethylamide), which is being evaluated for the treatment of major depressive disorder and anxiety disorder.
Lead Product(s): 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area: Psychiatry/Psychology Product Name: BETR-001
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $1.1 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 03, 2024
Details:
The net proceeds will advance the development its lead compound, BETR-001, a proprietary 2-bromo-LSD, a non-hallucinogenic derivative of lysergic acid diethylamide (LSD), in developement for the treatment of major depressive disorder, anxiety disorder and neuropathic pain.
Lead Product(s): 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area: Psychiatry/Psychology Product Name: BETR-001
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing January 02, 2024
Details:
BETR-001 (2-bromo-LSD) is a non-hallucinogenic and noncontrolled LSD derivative in development for treatment of major depressive disorder, anxiety disorder and neuropathic pain and other neuro-psychiatric and neurological disorders.
Lead Product(s): 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area: Psychiatry/Psychology Product Name: BETR-001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2023
Details:
BETR-001 (2-bromo-LSD) is a non-hallucinogenic and noncontrolled LSD derivative in development for treatment of major depressive disorder, anxiety disorder and neuropathic pain and other neuro-psychiatric and neurological disorders.
Lead Product(s): 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area: Psychiatry/Psychology Product Name: BETR-001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2023
Details:
BETR-001 (2-bromolysergic acid diethylamide), which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self administered.
Lead Product(s): 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area: Psychiatry/Psychology Product Name: BETR-001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Negev Capital
Deal Size: $0.4 million Upfront Cash: Undisclosed
Deal Type: Private Placement December 07, 2022
Details:
BETR-001 (2-bromolysergic acid diethylamide) is a second-generation LSD derivative molecule that does not cause hallucinations. The synthesis of BETR-001 is via non-controlled substance synthetic route, and therefore not subject to controlled substance regulatory restrictions.
Lead Product(s): 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area: Psychiatry/Psychology Product Name: BETR-001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2022
Details:
BETR-001 (2-Bromolysergic Acid Diethylamide), is a second-generation Lysergic Acid Diethylamide (“LSD”) derivative molecule that BetterLife believes will mimic the therapeutic potential of LSD without causing psychedelic effects, such as hallucinations.
Lead Product(s): 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area: Psychiatry/Psychology Product Name: BETR-001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Carleton University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 06, 2022
Details:
BETR-001 is a non-hallucinogenic Lysergic Acid Diethylamide derivative molecule. BETR-001 is a uniquely positioned LSD derivative with the potential to be as effective as LSD in various neuropsychiatric and neurological disorders without the burden of being hallucinogenic.
Lead Product(s): 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area: Psychiatry/Psychology Product Name: BETR-001
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2022
Details:
The study demonstrated that treatment of rat embryonic cortical neurons with BETR-001 increases structural complexity of neurons (dendrite growth and complexity) and therefore, provides evidence of neural plasticity activity of BETR-001.
Lead Product(s): 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area: Psychiatry/Psychology Product Name: BETR-001
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2022
Details:
Key PK data points from the mouse study demonstrated that BETR-001 appeared quickly (10 minutes post dose) in the plasma and brain of mice following a single dose and remained detectable up to 8 hours post dose.
Lead Product(s): 2-Bromo-Lysergic Acid Diethylamide
Therapeutic Area: Psychiatry/Psychology Product Name: BETR-001
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Nucro-Technics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
